Up next

Autoplay

Treatment With Eribulin Mesylate in Metastatic Breast Cancer

4 Views • 07/03/23
Share
Embed
administrator
administrator
Subscribers
0

In this segment, panelists explore the cytotoxic agent eribulin mesylate, which has been the focus of several recent clinical trials. In all, despite a growing focus on targeted therapies, cytotoxics remain an important class of drugs in the treatment of patients with metastatic breast cancer.

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay